SWTX 250502 46.00C(SWTX250502C46000) Stock Price Today

0.10
+0.05+100.00%

15min DelayTrading Apr 30 12:41 ET

0.20High0.10Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Teddy123

Apr 28 14:21

Pharmaceutical industry analysis

$SpringWorks Therapeutics (SWTX.US)$
Acquisition brings two FDA-approved rare tumor therapies to Merck KGaA's portfolio, creating leadership position in high-unmet-need markets.
This acquisition strategically enhances Merck KGaA's position in specialized rare tumor markets by adding two recently FDA-approved therapies with distinctive market positions. SpringWorks contributes OGSIVEO® (nirogacestat), a first-in-class therapy established as the systemic standard-of...

Teddy123

Apr 28 14:20

Financial Analysis

$SpringWorks Therapeutics (SWTX.US)$
Merck KGaA's $3.9B acquisition of SpringWorks offers 26% premium to shareholders while strategically expanding Merck's rare tumor portfolio.
The $47 per share all-cash acquisition of SpringWorks by Merck KGaA represents a 26% premium to SpringWorks' unaffected 20-day volume-weighted average price before market speculation. This translates to an equity value of approximately $3.9 billion and enterprise value of $3.4 billion (€3.0 billion), pr...

Teddy123

Apr 28 14:20

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

$SpringWorks Therapeutics (SWTX.US)$
Merck KGaA's $3.9B SpringWorks Acquisition Brings Revolutionary Rare Disease Treatments Under Its Wing

Teddy123

Apr 28 10:34

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

$SpringWorks Therapeutics (SWTX.US)$
EU Regulators Set to Rule on SpringWorks' Breakthrough Desmoid Tumor Treatment in Q2 2025

G3636G

Apr 28 09:29

Tarrif vs takeover. Is it cheaper to grant oversea companies to produce medicine

$SpringWorks Therapeutics (SWTX.US)$
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion - reuters.com/bus...
Exclusive: US pharma tariffs would raise US drug costs by $51 billion annually, report finds - reuters.com/bus...
It might cost cheaper to produce medicine 💊 oversea

SWTX250502C46000

News

Comments